Welcome to our dedicated page for QT Imaging Holdings news (Ticker: qti), a resource for investors and traders seeking the latest updates and insights on QT Imaging Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QT Imaging Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QT Imaging Holdings's position in the market.
QT Imaging (Nasdaq: QTI) received FDA 510(k) clearance on March 10, 2026 for an enhanced configuration of its Breast Acoustic CT scanner that improves visualization and expands coverage of posterior breast tissue.
The update uses a tilted transmitter geometry to better image breast tissue near the chest wall and continues to generate 3D tomographic images with quantified fibroglandular tissue volume (FGV) and FGV-to-total-breast-volume metrics.
QT Imaging (Nasdaq: QTI) appointed Dr. Mary W. Yamashita as Medical Advisor effective March 4, 2026. Dr. Yamashita will advise on clinical interpretation standards, structured reporting, training, and reader study design to support clinical integration of QT Imaging’s radiation-free 3D breast imaging technology.
She is Section Chief of Breast Imaging at USC Keck School of Medicine and Medical Director of mammography at two USC breast centers; her experience includes multicenter trials, research, and resident/fellow mentorship.
QT Imaging (Nasdaq: QTI) announced AMA approval of a new Category III CPT code X579T for 3D quantitative transmission volumetric ultrasound tomography of the breast. The code will be released July 1, 2026, and becomes effective January 1, 2027, enabling standardized reporting and commercial opportunities with hospitals.
The designation recognizes the technology as a distinct clinical service, supports utilization tracking and data collection, and is described as a step toward broader reimbursement and adoption.
QT Imaging (Nasdaq: QTI) reported preliminary unaudited results for Q4 and full year 2025. Q4 revenue $8.3M on shipments of 17 scanners; 2025 revenue $18.9M on 40 scanners, above $18.0M guidance. Gross margin declined to 45% for 2025; cash and equivalents $10.5M as of Dec 31, 2025.
Strengthened capital with a $18.2M private placement, relisted on Nasdaq, and announced collaborations with Intelerad and Olea. Secured UAE distribution with committed minimum orders of 43 scanners (>$24M revenue). 2026 revenue outlook: ~$39M.
QT Imaging (NASDAQ: QTI) announced that Chief Science Officer Bilal Malik, Ph.D. will present at SPIE Medical Imaging 2026 in Vancouver, Feb 15–19, 2026. His oral talk, “Automated breast boundary extraction from reflection data in breast acoustic CT,” details a multi-step, validated algorithm integrated into company production software.
The method supports image reconstruction, reflection gain calculation, denoising, breast density calculation, and underpins planned AI/ML initiatives for lesion segmentation and clinical decision support.
QT Imaging Holdings (NASDAQ:QTI) has announced the release of a new machine learning-enabled image interpolation algorithm that reduces scan times by approximately 50%. The technology allows the system to skip alternate scan levels while maintaining high image quality and diagnostic accuracy.
The advancement aims to enhance patient comfort through shorter scanning times and improve operational efficiency by increasing patient throughput. The company will present this development at the SPIE Medical Imaging 2025 conference in San Diego.
QTI continues to expand its clinical and R&D efforts through collaborations with institutions including the National Institutes of Health, Sunnybrook Health Sciences Centre, and the Stephenson Cancer Center at the University of Oklahoma, focusing on advancing cancer detection and treatment precision.
QT Imaging Holdings (NASDAQ:QTI), a medical device company, announces the elimination of its short-term liabilities and forecasts robust revenue growth for 2025 and 2026. The company has amended its convertible promissory notes with YA II PN, and Funicular Funds, LP, extending the maturity date to March 31, 2026, with no payments due until then. QT Imaging projects revenue of $18M in 2025 and $27M in 2026, a significant increase from 2024. The company aims to deliver a minimum of 40 scanners in 2025 and 60 scanners in 2026, totaling $45M in revenue over the two years. Further details are available in the SEC Form 8-K filed on January 10, 2025.
QT Imaging Holdings (NASDAQ:QTI) has announced the expansion of its Breast Acoustic CT Scanner to Couri Center for Gynecology and Integrative Women's Health in Peoria, IL. The shipment was executed in partnership with NXC Imaging, Inc. The technology offers enhanced breast imaging capabilities, particularly beneficial for patients with dense breasts and those at elevated risk of breast cancer. The system provides painless, true 3D imaging with high resolution. QTI will present its technology at the Empowered Wellness: A Women's Health Summit on March 8, 2025, sponsored by the Couri Center.
QT Imaging Holdings (NASDAQ:QTI) announces its participation in the Radiological Society of North America 2024 Annual Meeting in Chicago, December 1-5, 2024. Dr. Bilal Malik, Chief Science Officer, will present on December 4th at 9:30 am, focusing on Breast Ultrasound Techniques. His presentation will compare quantitative transmission ultrasound imaging with digital breast tomosynthesis (DBT), showcasing results from a multi-reader, multi-case observer study.
The study demonstrates QTI's technology performs comparably to DBT, potentially offering a safe and more accessible option for breast cancer screening and diagnosis.
QT Imaging Holdings (NASDAQ: QTI) reported Q3 2024 financial results with commercial revenue of $1.0 million, including $0.9 million from scanner sales. The company achieved a gross margin of 63%, up from 51% in Q2 2024. Net loss was $3.6 million, including $1.5 million in convertible note interest expenses. The company completed an engineering and clinical feasibility study with its strategic partner and secured a $2.56 million PIPE investment from board members. QTI also amended its convertible note with YA II PN, reducing the principal balance to $8.6 million and extending maturity to March 2026.